HA-WBRT-SIB for Brain Metastasis of Lung Cancer

Status Completed

Clinical Trial Summary

Patients with lung cancer and brain metastases undergo HA-WBRT-SIB using image-guided radiotherapy, receiving a total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV is boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week. The optimal mean dose (Dmean) to the bilateral hippocampus should optimally be ≤ 8 Gy, with a mandatory maximum dose (Dmax) to the hippocampus not exceeding 10 Gy; the preferred Dmean to the hippocampus PRV should optimally be ≤ 9 Gy, while the mandatory Dmax to the hippocampus PRV should be ≤ 12 Gy. The HVLT-R immediate recall scores are obtained at baseline and 1, 3, and 6 months after treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06289023
Study type	Interventional
Source	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	January 1, 2016
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04074096` - Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis	Phase 2
Recruiting	`NCT04474925` - Pre- Versus Post-operative SRS for Resectable Brain Metastases	Phase 3
Recruiting	`NCT05358340` - Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions	N/A
Recruiting	`NCT05559853` - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Completed	`NCT03189381` - Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases	N/A
Completed	`NCT02082587` - Toronto BNB Pilot Study	N/A
Terminated	`NCT01551680` - A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases	Phase 1
Terminated	`NCT00717275` - Study of Temozolomide to Treat Newly Diagnosed Brain Metastases	Phase 2
Recruiting	`NCT05048212` - A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases	Phase 2
Recruiting	`NCT03714243` - Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases	N/A
Recruiting	`NCT05573815` - Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT05452005` - Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT06457906` - SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC	Phase 3
Completed	`NCT04170777` - Perfexion Registration Using CBCT
Recruiting	`NCT03027544` - Tomotherapy for Refractory Brain Metastases	N/A
Completed	`NCT04178330` - Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases	N/A
Terminated	`NCT02187822` - Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases	Phase 1
Terminated	`NCT00538343` - RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases	Phase 2